Payment overview · 2025
General Payments
$477.87
21 reported records · 11 companies
Healthcare provider profile · identity verified
Kirk Uomoto, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1578510426
Verified facts
What the public records show
CMS Open Payments records show Kirk Uomoto, MD received $477.87 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 348 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 426 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 348 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $137.28 | 28.7% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $79.48 | 16.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.67 | 12.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.08 | 7.1% | 2 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $33.59 | 7.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.87 | 5.6% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $24.91 | 5.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.91 | 5.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.41 | 4.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.92 | 4.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.75 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $477.87 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $137.28 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $79.48 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.67 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.08 | 2 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 426 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 118 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 348 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
118 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
348 | 28 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
426 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
348 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 989 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 896 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 678 | 91 |
| Gabapentin | Gabapentin | 530 | 84 |
| Famotidine | Famotidine | 499 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 493 | 108 |
| Metoprolol Tartrate | Metoprolol Tartrate | 478 | 75 |
| Losartan Potassium | Losartan Potassium | 462 | 77 |
| Eliquis | Apixaban | 426 | 57 |
| Furosemide | Furosemide | 401 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 396 | 67 |
| Donepezil Hcl | Donepezil Hcl | 377 | 56 |
| Omeprazole | Omeprazole | 374 | 65 |
| Jardiance | Empagliflozin | 348 | 28 |
| Memantine Hcl | Memantine Hcl | 343 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 340 | 66 |
| Metformin Hcl | Metformin Hcl | 322 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 291 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 286 | 51 |
| Lisinopril | Lisinopril | 268 | 49 |
| Mirtazapine | Mirtazapine | 251 | 52 |
| Levetiracetam | Levetiracetam | 236 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 215 | 47 |
| Trazodone Hcl | Trazodone Hcl | 209 | 39 |
| Potassium Chloride | Potassium Chloride | 194 | 40 |
| Carvedilol | Carvedilol | 192 | 30 |
| Finasteride | Finasteride | 191 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 178 | 30 |
| Warfarin Sodium | Warfarin Sodium | 168 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 161 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 35 |
| Prednisone | Prednisone | 156 | 58 |
| Doxazosin Mesylate | Doxazosin Mesylate | 150 | 22 |
| Simvastatin | Simvastatin | 144 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 49 |
| Atenolol | Atenolol | 120 | 23 |
| Divalproex Sodium | Divalproex Sodium | 119 | 24 |
| Januvia | Sitagliptin Phosphate | 119 | 13 |
| Latanoprost | Latanoprost | 119 | 22 |
| Farxiga | Dapagliflozin Propanediol | 118 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 18 |
| Celecoxib | Celecoxib | 112 | 27 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 112 | 43 |
| Montelukast Sodium | Montelukast Sodium | 109 | 19 |
| Allopurinol | Allopurinol | 107 | 17 |
| Xarelto | Rivaroxaban | 103 | 15 |
| Alendronate Sodium | Alendronate Sodium | 102 | 19 |
| Levofloxacin | Levofloxacin | 101 | 65 |
| Temazepam | Temazepam | 101 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 100 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 37 |
| Myrbetriq | Mirabegron | 94 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 91 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 88 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 88 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 85 | 18 |
| Meloxicam | Meloxicam | 83 | 21 |
| Ozempic | Semaglutide | 83 | 15 |
| Bethanechol Chloride | Bethanechol Chloride | 81 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 17 |
| Risperidone | Risperidone | 79 | 17 |
| Clonidine Hcl | Clonidine Hcl | 76 | 33 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 74 | 15 |
| Sodium Chloride | 0.9 % Sodium Chloride | 73 | 22 |
| Lorazepam | Lorazepam | 72 | 30 |
| Tramadol Hcl | Tramadol Hcl | 72 | 22 |
| Baclofen | Baclofen | 70 | 18 |
| Lactulose | Lactulose | 67 | 25 |
| Alprazolam | Alprazolam | 65 | 13 |
| Cephalexin | Cephalexin | 61 | 44 |
| Nifedipine Er | Nifedipine | 61 | suppressed |
| Pregabalin | Pregabalin | 60 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 60 | 13 |
| Buspirone Hcl | Buspirone Hcl | 59 | 12 |
| Procrit | Epoetin Alfa | 58 | suppressed |
| Timolol Maleate | Timolol Maleate | 58 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 39 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 56 | suppressed |
| Valsartan | Valsartan | 55 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 11 |
| Hydrocortisone | Hydrocortisone | 54 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 11 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | 17 |
| Entresto | Sacubitril/Valsartan | 51 | suppressed |
| Ertapenem | Ertapenem Sodium | 51 | 13 |
| Ezetimibe | Ezetimibe | 51 | suppressed |
| Nitroglycerin | Nitroglycerin | 51 | 20 |
| Dapagliflozin | Dapagliflozin Propanediol | 49 | 13 |
| Lidocaine | Lidocaine | 49 | 12 |
| Sodium Chloride | Sodium Chloride 0.45 % | 49 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Spironolactone | Spironolactone | 48 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Glipizide | Glipizide | 47 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 46 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | 11 |
| Novolog Flexpen | Insulin Aspart | 44 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 43 | suppressed |
| Primidone | Primidone | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Amantadine | Amantadine Hcl | 40 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | 14 |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 17 |
| Topiramate | Topiramate | 38 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Carisoprodol | Carisoprodol | 35 | suppressed |
| Epogen | Epoetin Alfa | 35 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 34 | suppressed |
| Colchicine | Colchicine | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 21 |
| Heparin Sodium | Heparin Sodium,porcine | 33 | 11 |
| Lokelma | Sodium Zirconium Cyclosilicate | 33 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 26 |
| Rivastigmine | Rivastigmine | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 23 |
| Azithromycin | Azithromycin | 31 | 29 |
| Ondansetron Odt | Ondansetron | 31 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 30 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | 13 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Acetazolamide | Acetazolamide | 28 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 28 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 15 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Nystatin | Nystatin | 25 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Nateglinide | Nateglinide | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Enbrel Sureclick | Etanercept | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Lumigan | Bimatoprost | 19 | suppressed |
| Otezla | Apremilast | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 19 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Enulose | Lactulose | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Travoprost | Travoprost | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 15 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Permethrin | Permethrin | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Klor-Con 8 | Potassium Chloride | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Rhopressa | Netarsudil Mesylate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Brinzolamide | Brinzolamide | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Kristalose | Lactulose | 11 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $477.87 · 21 records | AstraZeneca Pharmaceuticals LP | AFREZZA, CAPLYTA, ELIQUIS, ENTRESTO, FARXIGA, JARDIANCE, KISUNLA, LEQVIO, RELISTOR, REXULTI, Yescarta | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error